Senokot Max Strength.

The tablets contain standardised senna pods equivalent to a total sennoside content (calculated as sennoside B) of 15mg.

For excipients see 6.1.

Tablets.

For the relief of occasional or non-persistent constipation.

Route of administration

Oral.

Dosage

Adults, including elderly and children over 12: 1 tablet taken at night.

Children 12 and under: Consult your doctor.

Senokot Max Strength tablets should not be given when any undiagnosed acute or persistent abdominal symptoms are present.

If there is no bowel movement after three days, consult your doctor.

If laxatives are needed every day, or abdominal pain persists, consult your doctor.

None stated.

There is some evidence for the safety of senna in human pregnancy and it has been in use for many years without apparent ill-consequence. If laxative treatment is required during pregnancy, the product may be used. Clinical studies have shown that breast-fed infants of mothers taking Senokot did not show any side-effects to the drug.

None stated.

Temporary mild griping may occur.

Where diarrhoea is severe, conservative measures are usually sufficient; generous amounts of fluid, especially fruit drinks, should be given.

The sugar moiety of the sennosides is removed by bacteria in the large intestine releasing the active anthrone fraction. This stimulates peristalsis via the submucosal and myenteric nerve plexuses. Senna acts in 8-12 hours.

The action of the sennosides is colon specific and does not depend upon systemic absorption.

No preclinical findings of relevance to the prescriber have been reported.

Calcium phosphate

Maize starch

Lactose monohydrate (DC)

Magnesium stearate

None known.

Two years.

Do not store above 30°C. Store in the original package.

12, 24 or 48 tablets packed in UPVC/PVDC/Foil blisters, contained in a carton.

Not applicable

Reckitt Benckiser Healthcare (UK) Limited

Dansom Lane

Hull

HU8 7DS

United Kingdom

PL 00063/0118

19/06/2007

19/06/2007